Your browser doesn't support javascript.
loading
Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).
Kazani, Shamsah; Rowlands, David J; Bottoli, Ivan; Milojevic, Julie; Alcantara, Jose; Jones, Ieuan; Kulmatycki, Kenneth; Machineni, Surendra; Mostovy, Lidia; Nicholls, Ian; Nick, Jerry A; Rowe, Steven M; Simmonds, Nicholas J; Vegesna, Raju; Verheijen, Jeroen; Danahay, Henry; Gosling, Martin; Ayalavajjala, Phaninatha Sarma; Salman, Mohammed; Strieter, Robert.
  • Kazani S; Novartis Institutes for BioMedical Research, Cambridge, MA, United States; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Rowlands DJ; Novartis Institutes for BioMedical Research, Cambridge, MA, United States; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Bottoli I; Novartis Pharma AG, Basel, Switzerland. Electronic address: ivan.bottoli@novartis.com.
  • Milojevic J; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Alcantara J; Novartis Institutes for BioMedical Research, Cambridge, MA, United States; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Jones I; Novartis Institutes for BioMedical Research, Cambridge, MA, United States; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Kulmatycki K; Novartis Institutes for BioMedical Research, Cambridge, MA, United States; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Machineni S; Novartis Healthcare Private Limited, Hyderabad, India.
  • Mostovy L; Novartis Institutes for BioMedical Research, Cambridge, MA, United States; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Nicholls I; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Nick JA; National Jewish Health, Denver, CO, United States.
  • Rowe SM; University of Alabama at Birmingham, Birmingham, AL, United States.
  • Simmonds NJ; Adult Cystic Fibrosis Centre, Royal Brompton Hospital and Imperial College, London, United Kingdom.
  • Vegesna R; Novartis Pharmaceuticals corporation, East Hanover, NJ, United States.
  • Verheijen J; Novartis Institutes for BioMedical Research, Cambridge, MA, United States; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Danahay H; Enterprise Therapeutics, Brighton, United Kingdom.
  • Gosling M; Novartis Pharmaceuticals corporation, East Hanover, NJ, United States; Enterprise Therapeutics, Brighton, United Kingdom; Sussex Drug Discovery Centre, University of Sussex, Brighton, United Kingdom.
  • Ayalavajjala PS; Novartis Healthcare Private Limited, Hyderabad, India.
  • Salman M; Novartis Healthcare Private Limited, Hyderabad, India.
  • Strieter R; Novartis Institutes for BioMedical Research, Cambridge, MA, United States; Novartis Institutes for BioMedical Research, Basel, Switzerland.
J Cyst Fibros ; 20(2): 250-256, 2021 03.
Article en En | MEDLINE | ID: mdl-33293212
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piridinas / Fibrosis Quística / Agonistas de los Canales de Cloruro / Amidas Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piridinas / Fibrosis Quística / Agonistas de los Canales de Cloruro / Amidas Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male Idioma: En Año: 2021 Tipo del documento: Article